Navigation Links
A Once-Daily Oral Drug for Chronic Obstructive Pulmonary Disease That Treats COPD-Related Inflammation Could Achieve Blockbuster Status

Although Physicians Report Satisfaction with GlaxoSmithKline's Advair and Boehringer Ingelheim/Pfizer's Spiriva, Significant Need Remains for a Novel Anti-Inflammatory Drug, According to a New Report from Decision Resources

WALTHAM, Mass., Feb. 27 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that surveyed physicians indicate that a novel, non- steroidal, anti-inflammatory agent for COPD that improves lung function could capture a significant share of the COPD market by replacing GlaxoSmithKline's Advair (also marketed as Seretide and Adoair).

The new report entitled Chronic Obstructive Pulmonary Disease: Opportunity Lies in Drugs That Address COPD-Related Inflammation finds that an oral, once- daily drug that treats COPD-related inflammation and improves lung function could achieve blockbuster status by 2016. Although an effective anti- inflammatory drug for COPD could replace Advair, it would likely be used in combination with Boehringer Ingelheim/Pfizer's Spiriva, according to the report. Spiriva's efficacy, safety, and convenience make it the current gold standard treatment for COPD but Advair's higher price, longer presence on the market and high prescribing by doctors made Advair the COPD market-share leader in 2006.

The report also finds that, following its approval in 2011 for the indication, Forest Laboratories/Almirall Prodesfarma's aclidinium will become the clinical gold standard for COPD by 2016. Aclidinium, a long-acting muscarinic antagonist (LAMA), will achieve gold standard status by 2016 because of its faster onset of action when compared to Spiriva.

"Because Spiriva is the first-to-market LAMA and has extensive clinical data and physician experience, we don't expect aclidinium to immediately achieve wide acceptance upon launch as the gold standard for COPD as physicians must first gain clinical experience with the drug," said Regina Jammen, analyst at Decision Resources. "We expect that clinical trials, specifically the UPLIFT trial, will provide results showing the benefits of the long-term use of Spiriva in COPD patients, and these results are likely to be generalized to other agents in the LAMA drug class, such as aclidinium."

About the Report

Chronic Obstructive Pulmonary Disease: Opportunity Lies in Drugs That Address COPD-Related Inflammation is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price- per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.


SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Labopharms Once-Daily Tramadol Approved in South Korea and Australia
2. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
3. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
4. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
5. ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily)
6. Once-Daily Exjade(R) Shown to Remove Toxic Iron From the Heart and Liver, According to Data Presented at ASH
7. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
8. Labopharm appeals FDAs decision on once-daily tramadol
9. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
10. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
11. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from reveals that behind the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Surgical Procedure Volumes: Global Analysis (United States, ... Australia, Canada)" report to their offering. ... an essential tool for healthcare business planners, provides surgical ... looks at surgery trends with an in-depth analysis of ...
Breaking Medicine Technology: